JP2004501931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004501931A5 JP2004501931A5 JP2002505804A JP2002505804A JP2004501931A5 JP 2004501931 A5 JP2004501931 A5 JP 2004501931A5 JP 2002505804 A JP2002505804 A JP 2002505804A JP 2002505804 A JP2002505804 A JP 2002505804A JP 2004501931 A5 JP2004501931 A5 JP 2004501931A5
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- compound
- steroid
- alkyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- -1 steroid compound Chemical class 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- GQWMUYFHLXTTCZ-AQPQYAIKSA-N CCC[C@H](Cc1c2)C(C(C[C@H]3CCC(C4)=O)[C@](C)(CC5)[C@@]34O)C5c1ccc2O Chemical compound CCC[C@H](Cc1c2)C(C(C[C@H]3CCC(C4)=O)[C@](C)(CC5)[C@@]34O)C5c1ccc2O GQWMUYFHLXTTCZ-AQPQYAIKSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PUSKHXMZPOMNTQ-UHFFFAOYSA-N ethyl 2,1,3-benzoselenadiazole-5-carboxylate Chemical compound CCOC(=O)C1=CC=C2N=[Se]=NC2=C1 PUSKHXMZPOMNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00201986 | 2000-06-06 | ||
| EP00201986.7 | 2000-06-06 | ||
| PCT/EP2001/004868 WO2002000682A1 (en) | 2000-06-06 | 2001-05-01 | 16, 17-carbocyclic condensed steroid compounds having selective estrogenic activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004501931A JP2004501931A (ja) | 2004-01-22 |
| JP2004501931A5 true JP2004501931A5 (enExample) | 2008-06-19 |
| JP5095902B2 JP5095902B2 (ja) | 2012-12-12 |
Family
ID=8171601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002505804A Expired - Fee Related JP5095902B2 (ja) | 2000-06-06 | 2001-05-01 | 選択的エストロゲン活性を有する１６，１７−炭素環縮合ステロイド化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US7868193B2 (enExample) |
| EP (1) | EP1294739B1 (enExample) |
| JP (1) | JP5095902B2 (enExample) |
| KR (1) | KR100769865B1 (enExample) |
| CN (1) | CN1235908C (enExample) |
| AR (1) | AR028080A1 (enExample) |
| AT (1) | ATE293124T1 (enExample) |
| AU (2) | AU5838601A (enExample) |
| BR (1) | BR0111445A (enExample) |
| CA (1) | CA2410220C (enExample) |
| CZ (1) | CZ20024014A3 (enExample) |
| DE (1) | DE60110069T2 (enExample) |
| DK (1) | DK1294739T3 (enExample) |
| ES (1) | ES2240454T3 (enExample) |
| HU (1) | HUP0301190A3 (enExample) |
| IL (1) | IL152957A0 (enExample) |
| MX (1) | MXPA02012117A (enExample) |
| NO (1) | NO324247B1 (enExample) |
| PE (1) | PE20020214A1 (enExample) |
| PL (1) | PL203732B1 (enExample) |
| PT (1) | PT1294739E (enExample) |
| RU (1) | RU2255090C2 (enExample) |
| SK (1) | SK286852B6 (enExample) |
| TW (1) | TWI225068B (enExample) |
| WO (1) | WO2002000682A1 (enExample) |
| ZA (1) | ZA200209452B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367648B2 (en) | 2009-06-10 | 2013-02-05 | Msd Oss B.V. | Substituted 16,17-annellated steroid compounds for use in womens healthcare |
| TW201109346A (en) * | 2009-06-10 | 2011-03-16 | Organon Nv | Substituted 16,17-annellated steroid compounds for use in women's healthcare |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3194821A (en) * | 1963-12-30 | 1965-07-13 | Abbott Lab | 17alpha-substituted 17beta-hydroxyestrenes |
| CA2200423C (en) | 1996-03-26 | 2006-12-19 | Sietse Mosselman | Novel estrogen receptor |
| IL123195A (en) * | 1997-02-21 | 2002-11-10 | Akzo Nobel Nv | Steroid compounds with anti-pregnancy activity and against bone thinning, preparation and pharmaceutical preparations containing them |
-
2001
- 2001-04-17 TW TW090109186A patent/TWI225068B/zh not_active IP Right Cessation
- 2001-05-01 IL IL15295701A patent/IL152957A0/xx not_active IP Right Cessation
- 2001-05-01 EP EP01931676A patent/EP1294739B1/en not_active Expired - Lifetime
- 2001-05-01 RU RU2002135594/04A patent/RU2255090C2/ru not_active IP Right Cessation
- 2001-05-01 WO PCT/EP2001/004868 patent/WO2002000682A1/en not_active Ceased
- 2001-05-01 PL PL359238A patent/PL203732B1/pl not_active IP Right Cessation
- 2001-05-01 DK DK01931676T patent/DK1294739T3/da active
- 2001-05-01 US US10/297,706 patent/US7868193B2/en not_active Expired - Fee Related
- 2001-05-01 ES ES01931676T patent/ES2240454T3/es not_active Expired - Lifetime
- 2001-05-01 AT AT01931676T patent/ATE293124T1/de active
- 2001-05-01 BR BR0111445-0A patent/BR0111445A/pt not_active IP Right Cessation
- 2001-05-01 JP JP2002505804A patent/JP5095902B2/ja not_active Expired - Fee Related
- 2001-05-01 CZ CZ20024014A patent/CZ20024014A3/cs unknown
- 2001-05-01 AU AU5838601A patent/AU5838601A/xx active Pending
- 2001-05-01 AU AU2001258386A patent/AU2001258386B2/en not_active Ceased
- 2001-05-01 KR KR1020027016657A patent/KR100769865B1/ko not_active Expired - Fee Related
- 2001-05-01 MX MXPA02012117A patent/MXPA02012117A/es active IP Right Grant
- 2001-05-01 PT PT01931676T patent/PT1294739E/pt unknown
- 2001-05-01 HU HU0301190A patent/HUP0301190A3/hu unknown
- 2001-05-01 SK SK1707-2002A patent/SK286852B6/sk not_active IP Right Cessation
- 2001-05-01 CN CNB018107451A patent/CN1235908C/zh not_active Expired - Fee Related
- 2001-05-01 CA CA002410220A patent/CA2410220C/en not_active Expired - Fee Related
- 2001-05-01 DE DE60110069T patent/DE60110069T2/de not_active Expired - Lifetime
- 2001-05-03 PE PE2001000401A patent/PE20020214A1/es not_active Application Discontinuation
- 2001-05-04 AR ARP010102107A patent/AR028080A1/es unknown
-
2002
- 2002-11-20 ZA ZA200209452A patent/ZA200209452B/en unknown
- 2002-12-02 NO NO20025793A patent/NO324247B1/no not_active IP Right Cessation
-
2010
- 2010-06-15 US US12/816,058 patent/US20100249083A1/en not_active Abandoned
-
2011
- 2011-05-20 US US13/112,184 patent/US20110224183A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003531119A5 (enExample) | ||
| JP3814292B2 (ja) | エストラ−１，３，５（１０）−トリエン誘導体、これらの製造方法及びこれら化合物を含有する製薬組成物 | |
| TW518339B (en) | 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives | |
| JP4845320B2 (ja) | （７α，１１β）−ジメチル−１７β−ヒドロキシ−４−エストレン−３−オンの４−Ｎ−ブチルシクロヘキサン酸エステル及びウンデカン酸エステルの製造方法及びそれらの医学用途 | |
| AU4401100A (en) | Ent-steroids as selectively active estrogens | |
| CN1246865A (zh) | 具氟化17α－烷基链的抗孕激素活性类固醇 | |
| CN87105307A (zh) | 11β-(4-异丙烯基苯基)-4，9-雌二烯，其制法及含此化合物的药剂 | |
| CN114302889B (zh) | 用于制备高纯度的雌四醇的工业方法 | |
| CN1360589A (zh) | 口服活性雄激素 | |
| JP2000256390A (ja) | 性ステロイド活性を抑制するために用いるエストロゲン核誘導体の医薬組成物 | |
| CA2228803A1 (en) | Novel estrogens | |
| HUP9903353A2 (hu) | 7Alfa-/5-metil-amino-pentil/-ösztratriének, e vegyületeket tartalmazó gyógyszerkészítmények és ezek alkalmazása gyógyszerek előállítására | |
| HUP0200055A2 (hu) | 16-Hidroxi-ösztratriének és ezeket tartalmazó gyógyszerkészítmények | |
| JP2004501931A5 (enExample) | ||
| ES2286042T3 (es) | 18-nor-esteroides como estrogenos eficaces selectivamente. | |
| US10351587B2 (en) | Method of making and using 7α, 11β-dimethyl-17β-hydroxyestr-4-en-3-one 17-undecanoate | |
| US6677329B1 (en) | Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11 | |
| US6756366B1 (en) | Orally active androgens | |
| US7109360B1 (en) | 16-hydroxyestratrienes as selectively active estrogens | |
| CN1031061C (zh) | 14α，17α-桥亚乙基-16α-羟基-雌三烯的制备方法 | |
| JP2002539135A5 (enExample) | ||
| JPH09500891A (ja) | １５，１５−ジアルキル置換されたエストラジオール誘導体 | |
| JP2003523946A5 (enExample) | ||
| RU2002135594A (ru) | 16, 17-карбоциклические конденсированные стероидные соединения, обладающие селективной эстрогенной активностью | |
| ES2240454T3 (es) | Compuestos esteroideos con un carbociclo concensado en 16,17 que tienen actividad estrogenica selectiva. |